First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
Authors:
Open Access
- 4 December 2018
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 37 (3) , 507-518
Abstract
Summary: Background This first-in-human phase 1 study assessed the safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 to determine its maximum tolerated dose (MTD) and recommended dose (RD). Methods In this dose-escalation study with a 3 + 3 design, TAS-114 and S-1 were concurrently administered orally under fasting conditions at 5–240 mg/m 2 and 30–36 mg/m 2 , respectively, in patients with advanced solid tumors. Safety, efficacy, and pharmacokinetics (PK) were evaluated. Results Seventy-six patients were enrolled. The MTD and RD were TAS-114 200 mg/m 2 plus S-1 36 mg/m 2 and TAS-114 240 mg/m 2 plus S-1 30 mg/m 2 , respectively. Common treatment-related adverse events were anemia, lymphocytopenia, leukopenia, neutropenia, decreased appetite, rash, nausea, and pigmentation disorder. Partial response (PR) was observed in 10 patients (non-small cell lung cancer [NSCLC], n = 5; pancreatic neuroendocrine tumor, n = 2; gastric cancer, n = 2; gallbladder cancer, n = 1). Of these, four patients achieved PR despite prior treatment history with S-1. Patients administered TAS-114 exhibited linear PK and CYP3A4 induction, with no effect on the PK of S-1. Conclusion TAS-114 plus S-1 showed tolerable, safe, and potentially effective results. To confirm safety and efficacy, two phase 2 studies are ongoing in NSCLC and gastric cancer patients. Clinical trial registration ClinicalTrials.gov ( NCT01610479 ) .Keywords
This publication has 28 references indexed in Scilit:
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST StudyJournal of Clinical Oncology, 2013
- 65 TAS-114 Enhances S-1 Activity in Vivo When Used in CombinationEuropean Journal of Cancer, 2012
- Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patientsCancer Science, 2010
- Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future VistasJapanese Journal of Clinical Oncology, 2008
- Novel opportunities for thymidylate metabolism as a therapeutic targetMolecular Cancer Therapeutics, 2008
- Potential Regional Differences for the Tolerability Profiles of FluoropyrimidinesJournal of Clinical Oncology, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Targeted cancer therapyNature, 2004
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003